Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa’s lead product...

Founded in 2007
Total money raised: $253.1M

94063 700 Saginaw Drive

Redwood City
Redwood City
Updated on Oct 7, 2013
Relypsa at CrunchBase
Scott M. Rocklage Executive Chairman
Lance Berman Chief Medical Officer and Senior Vice President
Kristine M. Ball Senior Vice President, Chief Financial Officer
Wilhelm Stahl Senior Vice President, Pharmaceutical Operations
Ronald Krasnow Sr. VP, General Counsel
Jerry M. Buysse Chief Scientific Officer, Senior Vice President, Research
Vijay Lathi Board Director
Jennifer Chung Vice President, Commercial
Klaus Veitinger Vice Chairman
Ronald M. Hunt Board Member
Thomas J. Schuetz Board Member
Deepa R. Pakianathan
Gerrit Klaerner President, Member of Board of Directors
Claire Lockey Senior Vice President, Pharmaceutical Development and Regulatory Affairs
Paul J. Hastings Board Member
David W. J. McGirr Board Member
Jonathan Silverstein Board Member
Jay Shepard President and CEO
James A. Johnson CFO

September, 2013

Relypsa pitches $126M IPO as lead CKD drug nears moment of PhIII truth

August, 2012

Relypsa raised $80M in a Series C round

Relypsa Raises $80M Series C Financing, Gears Up for Phase III Clinical Trials

August, 2011

Relypsa raised $70.1M in a Series B round


September, 2010

Relypsa raised $70M in a Series B round from OrbiMed Advisors, New Leaf Venture Partners, 5AM Ventures, Delphi Ventures, Sprout Group, and Mediphase Venture Partners

Relypsa Raises $70M in Series B Financing

October, 2007

Relypsa raised $33M in a Series A round from 5AM Ventures, New Leaf Venture Partners, Sprout Group, Delphi Ventures, CMEA Ventures, and Mediphase Venture Partners

Amgen, Relypsa and the art of the biotech-spinout-startup-restart

Relypsa was founded on October, 2007